OpenURL Connection Search

Select item for more details and to access through your institution.

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
Published in:
2001
By:
- Warren BL;
- Eid A;
- Singer P;
- Pillay SS;
- Carl P;
- Novak I;
- Chalupa P;
- Atherstone A;
- Pénzes I;
- Kübler A;
- Knaub S;
- Keinecke H;
- Heinrichs H;
- Schindel F;
- Juers M;
- Bone RC;
- Opal SM;
- KyberSept Trial Study Group;
- Cook DJ;
- Warren, B L
Publication type:
journal article
Condition Factors and Length-Weight Relationships of Pond-Cultured Paddlefish Polyodon spathula with Reference to Other Morphogenetic Relationships.
Published in:
Journal of the World Aquaculture Society, 1993, v. 24, n. 3, p. 429, doi. 10.1111/j.1749-7345.1993.tb00176.x
By:
- Mims, Steven D.;
- Knaub, Richard S.
Publication type:
Article
Seasonal production of rainbow trout, Oncorhynchus mykiss (Walbaum), in ponds using different feeding practices.
Published in:
Aquaculture Research, 1991, v. 22, n. 3, p. 335, doi. 10.1111/j.1365-2109.1991.tb00524.x
By:
- TIDWELL, J. H.;
- WEBSTER, C. D.;
- KNAUB, R. S.
Publication type:
Article
Antithrombin III in patients with severe sepsis: a pharmacokinetic study.
Published in:
2000
By:
- Ilias, W.;
- List, W.;
- Decruyenaere, J.;
- Lignian, H.;
- Knaub, S.;
- Schindel, F.;
- Keinecke, H.-O.;
- Heinrichs, H.;
- Thijs, L. G.
Publication type:
journal article
Long‐term tolerability, immunogenicity and efficacy of Nuwiq® (human‐cl rhFVIII) in children with severe haemophilia A.
Published in:
Haemophilia, 2018, v. 24, n. 4, p. 595, doi. 10.1111/hae.13460
By:
- Klukowska, A.;
- Szczepański, T.;
- Vdovin, V.;
- Knaub, S.;
- Bichler, J.;
- Jansen, M.;
- Dzhunova, I.;
- Liesner, R. J.
Publication type:
Article
Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in previously treated patients with severe haemophilia A.
Published in:
Haemophilia, 2018, v. 24, n. 4, p. 619, doi. 10.1111/hae.13493
By:
- Dargaud, Y.;
- Negrier, C.;
- Rusen, L.;
- Windyga, J.;
- Georgiev, P.;
- Bichler, J.;
- Solomon, C.;
- Knaub, S.;
- Lissitchkov, T.;
- Klamroth, R.
Publication type:
Article
Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.
Published in:
Haemophilia, 2018, v. 24, n. 1, p. 70, doi. 10.1111/hae.13351
By:
- Zozulya, N.;
- Kessler, C. M.;
- Klukowska, A.;
- von Depka, M.;
- Hampton, K.;
- Hay, C. R. M.;
- Jansen, M.;
- Bichler, J.;
- Knaub, S.;
- Rangarajan, S.
Publication type:
Article
PK-guided personalized prophylaxis with Nuwiq® (human-cl rh FVIII) in adults with severe haemophilia A.
Published in:
Haemophilia, 2017, v. 23, n. 5, p. 697, doi. 10.1111/hae.13251
By:
- Lissitchkov, T.;
- Rusen, L.;
- Georgiev, P.;
- Windyga, J.;
- Klamroth, R.;
- Gercheva, L.;
- Nemes, L.;
- Tiede, A.;
- Bichler, J.;
- Knaub, S.;
- Belyanskaya, L.;
- Walter, O.;
- Pasi, K. J.
Publication type:
Article
Prophylaxis vs. on-demand treatment with Nuwiq® (Human-cl rh FVIII) in adults with severe haemophilia A.
Published in:
Haemophilia, 2016, v. 22, n. 3, p. 374, doi. 10.1111/hae.12859
By:
- Tiede, A.;
- Oldenburg, J.;
- Lissitchkov, T.;
- Knaub, S.;
- Bichler, J.;
- Manco‐Johnson, M. J.
Publication type:
Article
Novel, human cell line-derived recombinant factor VIII (Human-cl rh FVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.
Published in:
Haemophilia, 2016, v. 22, n. 2, p. 232, doi. 10.1111/hae.12797
By:
- Klukowska, A.;
- Szczepański, T.;
- Vdovin, V.;
- Knaub, S.;
- Jansen, M.;
- Liesner, R.
Publication type:
Article
Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety.
Published in:
Haemophilia, 2016, v. 22, n. 2, p. 225, doi. 10.1111/hae.12793
By:
- Lissitchkov, T.;
- Hampton, K.;
- Depka, M.;
- Hay, C.;
- Rangarajan, S.;
- Tuddenham, E.;
- Holstein, K.;
- Huth‐Kühne, A.;
- Pabinger, I.;
- Knaub, S.;
- Bichler, J.;
- Oldenburg, J.
Publication type:
Article
The first recombinant FVIII produced in human cells - an update on its clinical development programme.
Published in:
Haemophilia, 2014, v. 20, p. 1, doi. 10.1111/hae.12322
By:
- Valentino, L. A.;
- Negrier, C.;
- Kohla, G.;
- Tiede, A.;
- Liesner, R.;
- Hart, D.;
- Knaub, S.
Publication type:
Article

Found: 12

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Condition Factors and Length-Weight Relationships of Pond-Cultured Paddlefish Polyodon spathula with Reference to Other Morphogenetic Relationships.

Seasonal production of rainbow trout, Oncorhynchus mykiss (Walbaum), in ponds using different feeding practices.

Antithrombin III in patients with severe sepsis: a pharmacokinetic study.

Long‐term tolerability, immunogenicity and efficacy of Nuwiq<sup>®</sup> (human‐cl rhFVIII) in children with severe haemophilia A.

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq<sup>®</sup> (human‐cl rhFVIII) in previously treated patients with severe haemophilia A.

Efficacy and safety of Nuwiq<sup>®</sup> (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.

PK-guided personalized prophylaxis with Nuwiq<sup>®</sup> (human-cl rh FVIII) in adults with severe haemophilia A.

Prophylaxis vs. on-demand treatment with Nuwiq<sup>®</sup> (Human-cl rh FVIII) in adults with severe haemophilia A.

Novel, human cell line-derived recombinant factor VIII (Human-cl rh FVIII, Nuwiq<sup>®</sup>) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.

Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq<sup>®</sup>) in adults with severe haemophilia A: efficacy and safety.

The first recombinant FVIII produced in human cells - an update on its clinical development programme.